A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
Status: | Archived |
---|---|
Conditions: | Lymphoma |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | March 2009 |
End Date: | September 2012 |
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with
relapsed or refractory Hodgkin's lymphoma.
We found this trial at
6
sites
Click here to add this to my saved trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
Click here to add this to my saved trials
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials
University of Colorado, Boulder As the flagship university of the state of Colorado, CU-Boulder is...
Click here to add this to my saved trials
Roswell Park Cancer Center Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer...
Click here to add this to my saved trials
Click here to add this to my saved trials